Explore our blogs on various markets

Patient segmentation in cardiology helps hospitals and clinics group patients based on health risks, behavior, and outcomes.. This allows care teams to provide better, faster, and more personalized treatment.. With the rise of chronic heart diseases and growing data from EHRs and diagnostic tools, segmentation is now more important than ever....

WAYNE, Pa. (June 2, 2025) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing treatments for immuno-inflammatory diseases, has announced the initiation of a Phase 2 clinical trial of its leading drug candidate, bosakitug (ATI-045)....

Lund, Sweden - April 25, 2025: Camurus has announced a major regulatory milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for Oczyesa (CAM2029). This once-monthly treatment is designed for adult patients living with acromegaly, a rare hormonal disorder.. The recommendation is based on strong results from seven clinical trials, including two pivotal Phase 3 studies...

Intuitive’s da Vinci 5 Surgical Robot Approved for Use in Europe. Sunnyvale, California, July 2025 — Intuitive, a global leader in robotic-assisted surgery, has announced that its latest surgical robot, the da Vinci 5 Surgical System, has received CE Mark approval. This approval allows the use of the da Vinci 5 system for both adult and pediatric patients across Europe in a wide range of minimally invasive surgeries, including urologic, gynecologic, and general laparoscopic procedures....

Waltham, Massachusetts, July 28, 2025 — The United States Food and Drug Administration has officially approved Empaveli, also known as pegcetacoplan. This innovative treatment was developed by Apellis Pharmaceuticals. It is now the first approved therapy for two rare and serious kidney diseases...

August 2, 2025 | Thousand Oaks, CA — Amgen has officially announced Meritide (formerly MariTide, maridebart cafraglutide), its groundbreaking investigational therapy for obesity, type 2 diabetes, and related cardiometabolic conditions, marking a bold step forward in the global fight against metabolic disease.. A breakthrough in obesity and diabetes management. In results from its Phase 2 clinical trial, Meritide showed strong and steady weight loss in adults living with obesity, both with and without type 2 diabetes...

Eli Lilly has officially acquired Verve Therapeutics, a pioneering biotech company specializing in in vivo gene editing for cardiovascular disease. The deal, announced on July 25, 2025, is valued at up to $1.3 billion. . It includes an upfront cash payment of $10.50 per share and a contingent value right (CVR) that may provide an additional $3.00 per share if Verve’s lead candidate reaches a U.S...

On July 22, 2025, Sanofi announced a definitive agreement to acquire Vicebio, a clinical-stage biotechnology company developing next-generation respiratory vaccines. The deal is valued at $1.6 billion and includes a $1.15 billion upfront payment with up to $450 million in milestone-based payments. The acquisition aims to expand Sanofi’s respiratory vaccine portfolio through access to Vicebio’s proprietary Molecular Clamp technology....

Clinical development is a long and expensive process. It often takes years of planning, testing, and data collection to bring a new medicine to market. Even then, most clinical trials do not succeed...

Clinical trials help test if new medicines are safe and effective. But many trials fail to find enough people or keep them until the end. One reason is that trial designs often do not match what patients need or want....